A 1,803-patient randomized trial found DOAC blood thinners cut serious cardiovascular events by 69% in atrial fibrillation patients at intermediate stroke risk, a group where guidelines have long hedged. Major bleeding didn't rise, and ischemic strokes dropped sharply.

— via ScienceDaily